Amgen wins EU green light for first virus-based cancer drug

A first-in-class drug from Amgen based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months. The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness.
Read more: http://ift.tt/1R3NvfE